Monthly Archives: March 2023

Austin-based Genprex shares promising gene therapy developments for diabetes and cancer

Reprogramming the course of cancer and diabetes, Austin-based Genprex is on the cutting edge of technologies to address the biggest health concerns

Read More

Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies

Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options

Read More

Genprex’s Diabetes Gene Therapy Program: A Major Step Forward in the Fight Against Type 1 Diabetes

Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.

Read More

CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.

Read More

Genprex to Present at Bioprocessing Summit Conference

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies

Read More

Genprex to Participate in March Investor and Industry Conferences 

Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes

Read More